Abionyx: sales up in 1st half

(CercleFinance.com) - Abionyx Pharma posted sales of 2.
4 million euros for the first half of 2024, compared with 2.1 million for the same period in 2023, with the company reporting that it had not commissioned any studies from IRIS Pharma during the period.

With regard to the discovery and development of innovative therapies designed to improve patients' lives, the company continues to provide its bioproduct free of charge for compassionate access applications.

At June 30, 2024, Abionyx Pharma's cash position stood at 5.3 million euros, including the reimbursement of the Abionyx CIR and before the reimbursement of the IRIS CIR. Following its fund-raising at the end of June, it claims financial visibility until the end of 2025.

Copyright (c) 2024 CercleFinance.com. All rights reserved.